Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N05CM25
|
| gptkbp:CASNumber |
gptkb:110942-02-4
|
| gptkbp:developedBy |
gptkb:Merck_&_Co.
|
| gptkbp:hasMolecularFormula |
C23H23ClN6O2
|
| gptkbp:hasSMILES |
CN1CCN(CC1)C(=O)C2=CC(=C(C=C2)C)N3N=CC=N3
|
| gptkbp:hasUNII |
7X9Q64V895
|
| https://www.w3.org/2000/01/rdf-schema#label |
110942-02-4
|
| gptkbp:IUPACName |
[(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Belsomra
|
| gptkbp:mechanismOfAction |
orexin receptor antagonist
|
| gptkbp:molecularWeight |
450.92 g/mol
|
| gptkbp:name |
gptkb:Suvorexant
|
| gptkbp:PubChem_CID |
DB09025
46215917 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
MK-4305
|
| gptkbp:usedFor |
treatment of insomnia
|
| gptkbp:bfsParent |
gptkb:Proleukin
|
| gptkbp:bfsLayer |
6
|